文献速递妇科母胎医学

基因型与年龄影响高危人乳头瘤病毒持续感染风险

Genotype and age shape the risk of persistent high-risk human papillomavirus infections.
PubMed 文献 · Am J Obstet Gynecol · 2026-02-25

基于芬兰35,084名筛查女性的队列,分析14种高危HPV基因型的清除率与进展风险。持续感染中HPV52持续率最高(52.2%),HPV16进展风险最高(42.9%)。年轻女性(<45岁)进展率约为年长女性3倍,Group 3基因型进展风险显著低于Group 1。

要点

  • HPV52持续率最高(52.2%),其次HPV58(50.5%)、HPV31(50.4%)、HPV16(48.9%)
  • 持续感染者中22.3%进展为癌前病变,HPV16/58/33进展比例最高
  • 年轻女性(<45岁)Group 1和Group 2基因型进展率显著高于年长女性

核心结论

  • HPV16、58、33和52持续感染与最高进展风险相关,而Group 3基因型常持续但不导致癌前病变。
  • 年轻女性进展率约为年长女性3倍,提示需按基因型和年龄分层管理。

研究设计与样本

  • 分析芬兰国家宫颈癌筛查项目(2017-2019,坦佩雷地区)35,084名女性。
  • HPV阳性样本用Seegene Anyplex II HPV28检测 assay 对14种高危基因型分型。
  • 持续感染定义为间隔0.5至4年检出同一基因型,随访至2023年评估进展。

主要发现

  • 2,006名高危HPV阳性且细胞学为NILM/ASC-US的女性中,884名(44.1%)为持续感染。
  • 持续感染中22.3%(n=197)进展为癌前病变,HPV16、58、33的高级别病变或更差比例分别为42.9%、31.5%、31.3%。
  • 年轻女性(<45岁)Group 1和Group 2基因型进展率分别为36.7% vs 14.3%和34% vs 10.8%(年长女性)。
  • Group 3基因型进展风险显著低于Group 1(HR 0.32,95%CI 0.20-0.52),且清除更快(HR 1.43,95%CI 1.11-1.84)。
  • 65.3%的持续高危HPV感染自发清除。

关键数值与推荐

  • 持续感染定义为同一基因型间隔0.5至4年检出。
  • Group 1包括HPV16、18、45;Group 2包括HPV31、33、52、58;Group 3包括HPV35、39、51、56、59、66、68。

临床怎么用

  • 对持续高危HPV感染应结合基因型和年龄进行风险分层,而非仅凭持续状态判断。
  • HPV16、58、33、52持续感染及年轻女性需更密切随访。
  • Group 3基因型持续感染可考虑减少不必要的干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persistent high-risk human papillomavirus infection detected in cervical cancer screening warrants follow-up, yet genotype-specific persistence times and progression risks remain poorly defined. This knowledge is critical for risk assessment and management of persistent human papillomavirus infections. OBJECTIVE: To evaluate genotype-specific clearance rates and subsequent cervical disease risks for 14 persistent high-risk human papillomavirus genotypes over long-term follow-up, focusing on clearance patterns and implications for follow-up strategies. STUDY DESIGN: We analyzed 35,084 women from the Finnish national cervical cancer screening program (2017-2019, Tampere region). Human papillomavirus-positive samples were genotyped using the Seegene Anyplex II HPV28 Detection assay to identify 14 individual high-risk human papillomavirus genotypes. Persistence was defined as detection of the same genotype 0.5 to 4 years apart. Genotypes were grouped by carcinogenic risk, and multiple-genotype infections were categorized by the most oncogenic type; separate analyses of single-type infections were conducted. Women with mild cytology (Negative for Intraepithelial Lesion or Malignancy or Atypical Squamous Cells of Undetermined Significance) at baseline were followed through 2023 to assess genotype-specific persistence and progression to high-grade lesions or worse. Clearance of infections was evaluated using the Kaplan-Meier estimates and Cox regression. RESULTS: Among 2006 high-risk human papillomavirus-positive women with Negative for Intraepithelial Lesion or Malignancy/Atypical Squamous Cells of Undetermined Significance cytology, 884 (44.1%) women had a persistent high-risk human papillomavirus infection. Human papillomavirus 52 showed the highest persistence (52.2%) followed by human papillomavirus 58 (50.5%), human papillomavirus 31 (50.4%), and human papillomavirus 16 (48.9%). Overall, 22.3% (n=197) of persistent infections progressed to precancerous lesions, with the highest proportions of high-grade lesions or worse observed among human papillomavirus 16, 58, and 33 (42.9%, 31.5%, and 31.3%, respectively). Younger women (aged <45 years) exhibited significantly higher progression for Group 1 (human papillomavirus 16, 18, and 45) and Group 2 (human papillomavirus 31, 33, 52, and 58) genotypes compared with older women (36.7 vs 14.3% and 34% vs 10.8%, respectively). Less oncogenic Group 3 genotypes (human papillomavirus 35, 39, 51, 56, 59, 66, and 68) had a significantly lower risk of progression compared with Group 1 regardless of age (hazard ratio, 0.32; 95% confidence interval, 0.20-0.52) in 6-year follow-up. 65.3% of persistent high-risk human papillomavirus infections cleared spontaneously, and Group 3 genotypes were associated with faster clearance compared with Group 1 (hazard ratio, 1.43; 95% confidence interval, 1.11-1.84). CONCLUSION: Persistent infections with human papillomavirus 16, 58, 33, and 52 were associated with the highest risks of progression, whereas Group 3 genotypes frequently persisted without leading to precancerous lesions. Younger women demonstrated an approximately 3-fold higher progression rate compared with older women. These findings suggest that persistence alone may not uniformly reflect oncogenic potential. Incorporating genotype-specific and age-specific risk stratification into screening and follow-up protocols could enhance risk assessment, thereby enabling more precise targeting of resources and minimizing unnecessary interventions.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Numminen E, Leino A, Karhula Q, et al. Genotype and age shape the risk of persistent high-risk human papillomavirus infections. Am J Obstet Gynecol. 2026. PMID: 41759606. doi:10.1016/j.ajog.2026.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。